Daphne Day

2.8k total citations · 2 hit papers
64 papers, 2.0k citations indexed

About

Daphne Day is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Daphne Day has authored 64 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Daphne Day's work include Cancer Immunotherapy and Biomarkers (24 papers), CAR-T cell therapy research (10 papers) and Cancer Genomics and Diagnostics (9 papers). Daphne Day is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), CAR-T cell therapy research (10 papers) and Cancer Genomics and Diagnostics (9 papers). Daphne Day collaborates with scholars based in Australia, Canada and United States. Daphne Day's co-authors include Aaron R. Hansen, L.L. Siu, Tom Wei‐Wu Chen, Leila Khoja, Lillian L. Siu, B K Mandal, B C Morson, N.A. Buckell, Eva Segelov and J Powell-Tuck and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Daphne Day

56 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

2017 678 citations Daphne Day, Aaron R. Hansen et al. Annals of Oncology profile →
Immune Checkpoint Inhibitor Therapy in Oncology

2022 117 citations Daphne Day, Eva Segelov et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daphne Day Australia	17	1.2k	514	503	340	289	64	2.0k
Michael Gong United States	22	1.0k 0.8×	395 0.8×	658 1.3×	462 1.4×	258 0.9×	66	2.2k
Kyoo‐Hyung Lee South Korea	29	733 0.6×	245 0.5×	255 0.5×	498 1.5×	300 1.0×	168	2.6k
Clélia Coutzac France	14	1.5k 1.2×	346 0.7×	203 0.4×	512 1.5×	453 1.6×	46	2.2k
Filippo Navaglia Italy	27	608 0.5×	301 0.6×	905 1.8×	497 1.5×	296 1.0×	89	2.1k
Go Kimura Japan	25	550 0.4×	1.0k 2.0×	367 0.7×	321 0.9×	238 0.8×	167	2.4k
Joseph W. Kim United States	22	1.7k 1.4×	862 1.7×	909 1.8×	673 2.0×	110 0.4×	66	2.6k
Shih–Fan Kuan United States	24	672 0.5×	529 1.0×	391 0.8×	312 0.9×	269 0.9×	46	2.1k
Joseph P. Connor United States	27	814 0.7×	286 0.6×	394 0.8×	688 2.0×	340 1.2×	88	2.7k
Yanghee Woo United States	30	1.1k 0.9×	1.1k 2.2×	957 1.9×	181 0.5×	184 0.6×	125	2.7k
Dirk L. Stippel Germany	26	534 0.4×	535 1.0×	805 1.6×	235 0.7×	358 1.2×	133	2.0k

Countries citing papers authored by Daphne Day

Since Specialization

Citations

This map shows the geographic impact of Daphne Day's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daphne Day with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daphne Day more than expected).

Fields of papers citing papers by Daphne Day

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daphne Day. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daphne Day. The network helps show where Daphne Day may publish in the future.

Co-authorship network of co-authors of Daphne Day

This figure shows the co-authorship network connecting the top 25 collaborators of Daphne Day. A scholar is included among the top collaborators of Daphne Day based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daphne Day. Daphne Day is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desai, Jayesh, Sanjeev Deva, Bo Gao, et al.. (2025). A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results. Cancer Chemotherapy and Pharmacology. 95(1). 99–99.

Day, Daphne, Vinod Ganju, Ki Y. Chung, et al.. (2025). First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors. British Journal of Cancer. 132(10). 905–912. 3 indexed citations

Tran, Ben, Mark Voskoboynik, Johanna C. Bendell, et al.. (2024). A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. Immunotherapy. 16(11). 759–774. 5 indexed citations

Chan, Arlene, Daphne Day, Phuong Dinh, et al.. (2024). Abstract PS15-04: A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients. Cancer Research. 84(9_Supplement). PS15–4. 3 indexed citations

Grech, Lisa, et al.. (2024). COVID-19 Vaccine Acceptance, Hesitancy, and Uptake in People with Diabetes in Australia. Vaccines. 12(6). 662–662.

Cao, Kim, Daphne Day, Katie N. Evans, et al.. (2024). Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study. The Breast. 79. 103861–103861.

Choi, Tammie, Bryan Chan, Lisa Grech, et al.. (2023). Factors Influencing COVID-19 Vaccine Hesitancy among Patients with Serious Chronic Illnesses during the Initial Australian Vaccine Rollout: A Multi-Centre Qualitative Analysis Using the Health Belief Model. Vaccines. 11(2). 239–239. 4 indexed citations

Day, Daphne, Vinod Ganju, Ki Y. Chung, et al.. (2023). 1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors. Annals of Oncology. 34. S625–S625. 4 indexed citations

Day, Daphne, Val Gebski, John Simes, et al.. (2023). 586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. Annals of Oncology. 34. S426–S427. 1 indexed citations

10.

Zhao, Jun, Xinmin Yu, Dingzhi Huang, et al.. (2023). SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(2). e006055–e006055. 15 indexed citations

11.

Grech, Lisa, Bao Sheng Loe, Daphne Day, et al.. (2022). The Disease Influenced Vaccine Acceptance Scale-Six (DIVAS-6): Validation of a Measure to Assess Disease-Related COVID-19 Vaccine Attitudes and Concerns. Behavioral Medicine. 49(4). 402–411. 5 indexed citations

12.

Garland, Sheila N., Maria Ftanou, Daphne Day, et al.. (2022). The Sleep, Cancer and Rest (SleepCaRe) Trial: Rationale and design of a randomized, controlled trial of cognitive behavioral and bright light therapy for insomnia and fatigue in women with breast cancer receiving chemotherapy. Contemporary Clinical Trials. 120. 106877–106877. 6 indexed citations

13.

Gao, Bo, Zhao Ma, Dongmei Huang, et al.. (2022). 1P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC). Annals of Oncology. 33. S1–S1. 2 indexed citations

14.

Coward, Jermaine, Bo Gao, Mark Voskoboynik, et al.. (2021). 153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC). Annals of Oncology. 32. S1446–S1447. 2 indexed citations

15.

Day, Daphne, Amy Prawira, Anna Spreafico, et al.. (2020). Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Oral Oncology. 108. 104753–104753. 32 indexed citations

16.

Rudin, Charles M., Hardev Pandha, Sumati Gupta, et al.. (2018). Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients. Annals of Oncology. 29. viii732–viii732. 15 indexed citations

17.

Day, Daphne & Aaron R. Hansen. (2016). Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs. 30(6). 571–584. 90 indexed citations

18.

Day, Daphne & O. A. N. Husain. (1986). Biopsy pathology of the oesophagus, stomach and duodenum. 12 indexed citations

19.

Patterson, Jan E., et al.. (1986). Histological and histochemical changes in the columnar lined (Barrett's) oesophagus.. Gut. 27(9). 1062–1068. 62 indexed citations

20.

Buckell, N.A., S R Gould, Daphne Day, J E Lennard-Jones, & Alan M. Edwards. (1978). Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis.. Gut. 19(12). 1140–1143. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact